DCM
MYGN icon

Delpha Capital Management’s Myriad Genetics MYGN Stock Holding History

Delpha Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-545
Closed -$19K – 828
2017
Q4 		$19K Buy
+545
New +$18.4K 0.02% 801

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Delpha Capital Management's MYGN Position: Q1 2018 in Review

Delpha Capital Management sold out of Myriad Genetics (MYGN) in Q1 2018, closing a stake of 545 shares — an estimated $19K sold.

Delpha Capital Management first reported a position in MYGN in Q4 2017 and held it in 1 quarter. The position peaked at $19K in Q4 2017. 260 funds tracked by Wall St. Rank hold MYGN as of Q1 2018.

  • Delpha Capital Management reported no remaining Myriad Genetics position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 545 Myriad Genetics shares in Q1 2018, an estimated $19K.
  • Delpha Capital Management first reported a position in Myriad Genetics in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Myriad Genetics position peaked at $19K in Q4 2017.
  • 260 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.